NCT00243854View on ClinicalTrials.gov

Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

August 31, 2010

Study Completion Date

October 31, 2011

Conditions
Pancreatic Cancer
Interventions
DRUG

Tarceva

Tarceva: 100mg/day x 2 weeks (Days 1-14) +

Trial Locations (1)

46202

Indiana University Cancer Center, Indianapolis

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Indiana University School of Medicine

OTHER

NCT00243854 - Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter